Anemia is the most common extraintestinal systemic complication of inflammatory bowel disease. Iron deficiency anemia and anemia of chronic disease are among the most frequent types. Intestinal iron absorption is controlled by the activity of ferroportin. Cells with high expression of ferroportin include enterocytes, and also macrophages and hepatocytes. Iron homeostasis is controlled by the hepcidin-ferroportin axis. Hepcidin is a central regulator of iron metabolism and can also serve as a marker of systemic inflammation. During systemic inflammatory response, the synthesis of hepcidin increases, and hepcidin binds to ferroportin and inhibits its activity. Thus, iron is not absorbed from the bowel into the circulation and also remains sequestered in macrophages. Conversely, hepcidin synthesis is suppressed during conditions requiring increased iron intake for enhanced erythropoiesis, such as iron deficiency anemia or hypoxia. Here, ferroportin is not blocked, and iron is actively absorbed into the bloodstream and also released from the stores. Production of hepcidin is influenced by the status of total body iron stores, systemic inflammatory activity and erythropoietic activity. Oral iron therapy is limited in inflammatory bowel diseases due to ongoing gastrointestinal inflammation. It is less effective and may worsen the underlying disease. Therefore, the choice between oral and parenteral iron therapy must be made with caution. Oral iron would be ineffective at high hepcidin levels due to concurrent ferroportin blockage. Contrarily, low levels of hepcidin indicate that oral iron therapy should be successful. An understanding of hepcidin can help in understanding the body's reaction to iron depletion during the inflammatory process.

Department of Pediatrics Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc 1 P Pavlova 185 6 Olomouc 779 00 Czech Republic

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc Olomouc Czech Republic

Zobrazit více v PubMed

Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010;6:659–666. PubMed DOI PMC

Sýkora J, Pomahačová R, Kreslová M, et al. Current global trends in the incidence of pediatric-onset inflammatory bowel disease. World J Gastroenterol.. 2018;24:2741–2763. PubMed DOI PMC

Bronský J, Beránková K, Černá Z, et al. Doporučení Pracovní skupiny dětské gastroenterologie a výživy ČPS pro diagnostiku a léčbu nespecifických střevních zánětů u dětí – doplněk k 1. vydání. Gastroent Hepatol. 2017;71:11–18. DOI

Adamcová M, Bajer M, Bajerová K, et al. Doporučení Pracovní skupiny dětské gastroenterologie a výživy při ČPS pro diagnostiku a léčbu nespecifických střevních zánětů u dětí. Čes-slov Pediat. 2012;67:4.

Wiskin AE, Fleming BJ, Wootton SA, et al. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis. 2012;6:687–691. PubMed DOI PMC

Wells CW, Lewis S, Barton JR, et al. Effects of changes in haemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–130. PubMed DOI PMC

Patel D, Trivedi C, Khan N. Management of anemia in patients with Inflammatory Bowel Disease (IBD). Curr Treat Options Gastroenterol. 2018;16:112–128. PubMed DOI PMC

Wallace DF. The regulation of iron absorption and homeostasis. Clin Biochem Rev. 2016;37:51–62. PubMed PMC

Ganz T. Iron and infection [published correction appears in Int J Hematol. 2017 Dec 2]. Int J Hematol. 2018;107:7–15.

Camaschella C. Regulation of iron balance. https://www.uptodate.com/contents/regulation-of-iron-balance . Accessed 9 Apr 2020.

Daher R, Manceau H, Karim Z. Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease. Presse Med. 2017;46:e272–e278. PubMed DOI PMC

Cui Y, Wu Q, Zhou Y. Iron-refractory iron deficiency anemia: new molecular mechanisms. Kidney Int. 2009;76:1137–1141. PubMed DOI PMC

Park CH, Valore EV, Waring AJ, et al. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806–7810. PubMed DOI PMC

Krawiec P, Mroczkowska-Juchkiewicz A, Pac-Kożuchowska E. Serum hepcidin in children with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:2165–2171. PubMed DOI PMC

Krawiec P, Pac-Kozuchowska E. The role of hepcidin in iron metabolism in inflammatory bowel diseases. Postepy Hig Med Dosw (Online). 2014;68:936–943. DOI

Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131:1790–1794. PubMed DOI PMC

Dignass A, Farrag K, Stein J. Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions. Int J Chronic Dis. 2018;2018:9394060. PubMed PMC

Bergamaschi G, Di Sabatino A, Albertini R, et al. Serum hepcidin in inflammatory bowel diseases: biological and clinical significance. Inflamm Bowel Dis. 2013;19:2166–2172. PubMed DOI PMC

Piperno A, Pelucchi S, Mariani R. Inherited iron overload disorders. Transl Gastroenterol Hepatol. 2020;5:25. https://doi.org/10.21037/tgh.2019.11.15 . PubMed DOI PMC

Daher R, Karim Z. Iron metabolism: state of the art. Transfus Clin Biol. 2017;24:115–119. PubMed DOI PMC

Zhang AS, Anderson SA, Wang J, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood. 2011;117:1687–1699. PubMed DOI PMC

Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94:1748–1752. PubMed DOI PMC

van der Vorm LN, Hendriks JC, Laarakkers CM, et al. Toward worldwide hepcidin assay harmonization: identification of a commutable secondary reference material. Clin Chem. 2016;62:993–1001. PubMed DOI PMC

Wolff F, Deleers M, Melot C, et al. Hepcidin-25: Measurement by LC–MS/MS in serum and urine, reference ranges and urinary fractional excretion. Clin Chim Acta. 2013;423:99–104. PubMed DOI PMC

Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, et al. Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood. 2011;117:e218–e225. PubMed DOI PMC

Sdogou T, Tsentidis C, Gourgiotis D, et al. Immunoassay-based serum hepcidin reference range measurements in healthy children: differences among age groups. J Clin Lab Anal. 2015;29:10–14. PubMed DOI PMC

Uijterschout L, Swinkels DW, Domellöf M, et al. Serum hepcidin measured by immunochemical and mass-spectrometric methods and their correlation with iron status indicators in healthy children aged 0.5–3 years. Pediatr Res. 2014;76:409–414. PubMed DOI PMC

Cangemi G, Pistorio A, Miano M, et al. Diagnostic potential of hepcidin testing in pediatrics. Eur J Haematol. 2013;90:323–330. PubMed DOI PMC

Oustamanolakis P, Koutroubakis IE, Messaritakis I, et al. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:262–268. PubMed DOI PMC

Mecklenburg I, Reznik D, Fasler-Kan E, et al.; Swiss IBD Cohort Study Group. Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease. J Crohns Colitis. 2014;8:1392–1397. PubMed DOI PMC

Martinelli M, Strisciuglio C, Alessandrella A, et al. Serum hepcidin and iron absorption in paediatric inflammatory bowel disease. J Crohns Colitis. 2016;10:566–574. PubMed DOI PMC

Bonovas S, Fiorino G, Allocca M, et al. Intravenous versus oral iron for the treatment of anemia in Inflammatory Bowel Disease: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95:e2308. DOI

Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol.. 2005;40:1058–1065. PubMed DOI PMC

Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haematologica.. 2020;105:260–272. PubMed DOI PMC

Aksan A, Wohlrath M, Iqbal TH, et al. Serum hepcidin levels predict intestinal iron absorption in patients with Inflammatory Bowel Disease. Clin Lab. 2019. https://doi.org/10.7754/clin.lab.2019 . PubMed DOI PMC

Camaschella C. New insights into iron deficiency and iron deficiency anemia. Blood Rev. 2017;31:225–233. PubMed DOI PMC

Reifen R, Matas Z, Zeidel L, et al. Iron supplementation may aggravate inflammatory status of colitis in a rat model. Dig Dis Sci. 2000;45:394–397. https://doi.org/10.1023/a:1005437331967 . PubMed DOI PMC

Carrier J, Aghdassi E, Platt I, et al. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001;15:1989–1999. PubMed DOI PMC

Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire. Am J Clin Nutr. 2010;92:1406–1415. PubMed DOI PMC

Lee T, Clavel T, Smirnov K, et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut. 2017;66:863–871. PubMed DOI PMC

Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One.. 2015;10:e0117383. PubMed DOI PMC

Lee TW, Kolber MR, Fedorak RN, et al. Iron replacement therapy in inflammatory bowel disease patients with iron deficiency anemia: a systematic review and meta-analysis. J Crohns Colitis. 2012;6:267–275. PubMed DOI PMC

Karaskova E, Volejnikova J, Holub D, et al. Hepcidin in newly diagnosed inflammatory bowel disease in children. J Paediatr Child Health. 2018;54:1362–1367. PubMed DOI PMC

Karaskova E, Volejnikova J, Holub D, et al. Changes in serum hepcidin levels in children with inflammatory bowel disease during anti-inflammatory treatment. J Paediatr Child Health.. 2020;56:276–282. PubMed DOI PMC

Moran-Lev H, Galai T, Yerushalmy-Feler A, et al. Vitamin D decreases hepcidin and inflammatory markers in newly diagnosed Inflammatory Bowel Disease Paediatric patients: a prospective study. J Crohns Colitis.. 2019;13:1287–1291. PubMed DOI PMC

Bacchetta J, Zaritsky JJ, Sea JL, et al. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol.. 2014;25:564–572. PubMed DOI PMC

Cavallaro F, Duca L, Pisani LF, et al. Anti-TNF-mediated modulation of prohepcidin improves iron availability in Inflammatory Bowel Disease, in an IL-6-mediated fashion. Can J Gastroenterol Hepatol. 2017;2017:6843976. PubMed DOI PMC

Atkinson MA, Leonard MB, Herskovitz R, et al. Changes in hepcidin and hemoglobin after anti-TNF-alpha therapy in children and adolescents with crohn disease. J Pediatr Gastroenterol Nutr. 2018;66:90–94. PubMed DOI PMC